[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.175.191.72. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
October 1999

Photodynamic Therapy With Verteporfin Is Effective for Selected Patients With Neovascular Age-related Macular Degeneration

Arch Ophthalmol. 1999;117(10):1400-1402. doi:10.1001/archopht.117.10.1400

THIS ISSUE OF THE ARCHIVES provides information about a promising new treatment for age-related macular degeneration (AMD), the major cause of severe and irreversible vision loss in the United States and in many developed countries. The article,1 as well as 2 others published in the September issue of the ARCHIVES,2,3 describes a series of research projects carried out by investigators in North America and Europe to evaluate photodynamic therapy as a treatment for choroidal neovascularization (CNV), the type of late AMD that is the most frequent cause of visual loss to the level of legal blindness and worse.

×